Wellgistics shares surge 14.26% intraday after announcing $70B market breakthrough with Forzet targeting Ozempic/GLP-1 muscle loss.

lunes, 23 de marzo de 2026, 9:38 am ET1 min de lectura
WGRX--
Wellgistics Health, Inc. surged 14.26% intraday after announcing a strategic initiative to target a $70 billion market addressing Ozempic/GLP-1 muscle loss with its Forzet™ solution and strengthening its PharmacyChain™ platform with insurance partnerships. The move highlights the company’s expansion into a high-growth therapeutic area and enhanced pharmacy network optimization.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios